The established status epilepticus trial 2013

Thomas Bleck, Hannah Cock, James Chamberlain, James Cloyd, Jason Connor, Jordan Elm, Nathan Fountain, Elizabeth Jones, Daniel Lowenstein, Shlomo Shinnar, Robert Silbergleit, David Treiman, Eugen Trinka, Jaideep Kapur

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Benzodiazepine-refractory status epilepticus (established status epilepticus, ESE) is a relatively common emergency condition with several widely used treatments. There are no controlled, randomized, blinded clinical trials to compare the efficacy and tolerability of currently available treatments for ESE. The ESE treatment trial is designed to determine the most effective and/or the least effective treatment of ESE among patients older than 2 years by comparing three arms: fosphenytoin (fPHT) levetiracetam (LVT), and valproic acid (VPA). This is a multicenter, randomized, double-blind, Bayesian adaptive, phase III comparative effectiveness trial. Up to 795 patients will be randomized initially 1:1:1, and response-adaptive randomization will occur after 300 patients have been recruited. Randomization will be stratified by three age groups, 2-18, 19-65, and 66 and older. The primary outcome measure is cessation of clinical seizure activity and improving mental status, without serious adverse effects or further intervention at 60 min after administration of study drug. Each subject will be followed until discharge or 30 days from enrollment. This trial will include interim analyses for early success and futility. This trial will be considered a success if the probability that a treatment is the most effective is >0.975 or the probability that a treatment is the least effective is >0.975 for any treatment. Proposed total sample size is 795, which provides 90% power to identify the most effective and/or the least effective treatment when one treatment arm has a true response rate of 65% and the true response rate is 50% in the other two arms.

Original languageEnglish (US)
Pages (from-to)89-92
Number of pages4
JournalEpilepsia
Volume54
Issue numberSUPPL. 6
DOIs
StatePublished - 2013

Fingerprint

Status Epilepticus
etiracetam
Therapeutics
Random Allocation
Medical Futility
Valproic Acid
Benzodiazepines
Sample Size
Seizures
Emergencies
Randomized Controlled Trials
Age Groups
Outcome Assessment (Health Care)

Keywords

  • Bayesian design
  • Comparative efficacy
  • Fosphenytoin
  • Levetiracetam
  • Valproic acid

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Bleck, T., Cock, H., Chamberlain, J., Cloyd, J., Connor, J., Elm, J., ... Kapur, J. (2013). The established status epilepticus trial 2013. Epilepsia, 54(SUPPL. 6), 89-92. https://doi.org/10.1111/epi.12288

The established status epilepticus trial 2013. / Bleck, Thomas; Cock, Hannah; Chamberlain, James; Cloyd, James; Connor, Jason; Elm, Jordan; Fountain, Nathan; Jones, Elizabeth; Lowenstein, Daniel; Shinnar, Shlomo; Silbergleit, Robert; Treiman, David; Trinka, Eugen; Kapur, Jaideep.

In: Epilepsia, Vol. 54, No. SUPPL. 6, 2013, p. 89-92.

Research output: Contribution to journalArticle

Bleck, T, Cock, H, Chamberlain, J, Cloyd, J, Connor, J, Elm, J, Fountain, N, Jones, E, Lowenstein, D, Shinnar, S, Silbergleit, R, Treiman, D, Trinka, E & Kapur, J 2013, 'The established status epilepticus trial 2013', Epilepsia, vol. 54, no. SUPPL. 6, pp. 89-92. https://doi.org/10.1111/epi.12288
Bleck T, Cock H, Chamberlain J, Cloyd J, Connor J, Elm J et al. The established status epilepticus trial 2013. Epilepsia. 2013;54(SUPPL. 6):89-92. https://doi.org/10.1111/epi.12288
Bleck, Thomas ; Cock, Hannah ; Chamberlain, James ; Cloyd, James ; Connor, Jason ; Elm, Jordan ; Fountain, Nathan ; Jones, Elizabeth ; Lowenstein, Daniel ; Shinnar, Shlomo ; Silbergleit, Robert ; Treiman, David ; Trinka, Eugen ; Kapur, Jaideep. / The established status epilepticus trial 2013. In: Epilepsia. 2013 ; Vol. 54, No. SUPPL. 6. pp. 89-92.
@article{b530593ca1974a4892a3dea994e63cbf,
title = "The established status epilepticus trial 2013",
abstract = "Benzodiazepine-refractory status epilepticus (established status epilepticus, ESE) is a relatively common emergency condition with several widely used treatments. There are no controlled, randomized, blinded clinical trials to compare the efficacy and tolerability of currently available treatments for ESE. The ESE treatment trial is designed to determine the most effective and/or the least effective treatment of ESE among patients older than 2 years by comparing three arms: fosphenytoin (fPHT) levetiracetam (LVT), and valproic acid (VPA). This is a multicenter, randomized, double-blind, Bayesian adaptive, phase III comparative effectiveness trial. Up to 795 patients will be randomized initially 1:1:1, and response-adaptive randomization will occur after 300 patients have been recruited. Randomization will be stratified by three age groups, 2-18, 19-65, and 66 and older. The primary outcome measure is cessation of clinical seizure activity and improving mental status, without serious adverse effects or further intervention at 60 min after administration of study drug. Each subject will be followed until discharge or 30 days from enrollment. This trial will include interim analyses for early success and futility. This trial will be considered a success if the probability that a treatment is the most effective is >0.975 or the probability that a treatment is the least effective is >0.975 for any treatment. Proposed total sample size is 795, which provides 90{\%} power to identify the most effective and/or the least effective treatment when one treatment arm has a true response rate of 65{\%} and the true response rate is 50{\%} in the other two arms.",
keywords = "Bayesian design, Comparative efficacy, Fosphenytoin, Levetiracetam, Valproic acid",
author = "Thomas Bleck and Hannah Cock and James Chamberlain and James Cloyd and Jason Connor and Jordan Elm and Nathan Fountain and Elizabeth Jones and Daniel Lowenstein and Shlomo Shinnar and Robert Silbergleit and David Treiman and Eugen Trinka and Jaideep Kapur",
year = "2013",
doi = "10.1111/epi.12288",
language = "English (US)",
volume = "54",
pages = "89--92",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "SUPPL. 6",

}

TY - JOUR

T1 - The established status epilepticus trial 2013

AU - Bleck, Thomas

AU - Cock, Hannah

AU - Chamberlain, James

AU - Cloyd, James

AU - Connor, Jason

AU - Elm, Jordan

AU - Fountain, Nathan

AU - Jones, Elizabeth

AU - Lowenstein, Daniel

AU - Shinnar, Shlomo

AU - Silbergleit, Robert

AU - Treiman, David

AU - Trinka, Eugen

AU - Kapur, Jaideep

PY - 2013

Y1 - 2013

N2 - Benzodiazepine-refractory status epilepticus (established status epilepticus, ESE) is a relatively common emergency condition with several widely used treatments. There are no controlled, randomized, blinded clinical trials to compare the efficacy and tolerability of currently available treatments for ESE. The ESE treatment trial is designed to determine the most effective and/or the least effective treatment of ESE among patients older than 2 years by comparing three arms: fosphenytoin (fPHT) levetiracetam (LVT), and valproic acid (VPA). This is a multicenter, randomized, double-blind, Bayesian adaptive, phase III comparative effectiveness trial. Up to 795 patients will be randomized initially 1:1:1, and response-adaptive randomization will occur after 300 patients have been recruited. Randomization will be stratified by three age groups, 2-18, 19-65, and 66 and older. The primary outcome measure is cessation of clinical seizure activity and improving mental status, without serious adverse effects or further intervention at 60 min after administration of study drug. Each subject will be followed until discharge or 30 days from enrollment. This trial will include interim analyses for early success and futility. This trial will be considered a success if the probability that a treatment is the most effective is >0.975 or the probability that a treatment is the least effective is >0.975 for any treatment. Proposed total sample size is 795, which provides 90% power to identify the most effective and/or the least effective treatment when one treatment arm has a true response rate of 65% and the true response rate is 50% in the other two arms.

AB - Benzodiazepine-refractory status epilepticus (established status epilepticus, ESE) is a relatively common emergency condition with several widely used treatments. There are no controlled, randomized, blinded clinical trials to compare the efficacy and tolerability of currently available treatments for ESE. The ESE treatment trial is designed to determine the most effective and/or the least effective treatment of ESE among patients older than 2 years by comparing three arms: fosphenytoin (fPHT) levetiracetam (LVT), and valproic acid (VPA). This is a multicenter, randomized, double-blind, Bayesian adaptive, phase III comparative effectiveness trial. Up to 795 patients will be randomized initially 1:1:1, and response-adaptive randomization will occur after 300 patients have been recruited. Randomization will be stratified by three age groups, 2-18, 19-65, and 66 and older. The primary outcome measure is cessation of clinical seizure activity and improving mental status, without serious adverse effects or further intervention at 60 min after administration of study drug. Each subject will be followed until discharge or 30 days from enrollment. This trial will include interim analyses for early success and futility. This trial will be considered a success if the probability that a treatment is the most effective is >0.975 or the probability that a treatment is the least effective is >0.975 for any treatment. Proposed total sample size is 795, which provides 90% power to identify the most effective and/or the least effective treatment when one treatment arm has a true response rate of 65% and the true response rate is 50% in the other two arms.

KW - Bayesian design

KW - Comparative efficacy

KW - Fosphenytoin

KW - Levetiracetam

KW - Valproic acid

UR - http://www.scopus.com/inward/record.url?scp=84891530460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891530460&partnerID=8YFLogxK

U2 - 10.1111/epi.12288

DO - 10.1111/epi.12288

M3 - Article

C2 - 24001084

AN - SCOPUS:84891530460

VL - 54

SP - 89

EP - 92

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - SUPPL. 6

ER -